Excellergy Acquisition, Valuation, Funding & Investors

ataiBeckley is a biopharmaceutical firm advancing neuropsychiatric therapies through clinical trials. Its pipeline features BPL-003, an intranasal 5-MeO-DMT for treatment-resistant depression, alongside DMT buccal film and oral R-MDMA formulations. The company conducts Phase 2 studies for bipolar II disorder and major depressive disorder, emphasizing rapid-onset treatments for mental health conditions.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Anhui Anke Biotechnology (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceuticals and health-care products. The Company distributes its product in both domestic and overseas markets. The company operates in more than 30 provinces in China.

Guobang Pharma Ltd is engaged in the research and development, production and sales of related products in the field of medicine and animal health products.

PT Kalbe Farma Tbk is a drug manufacturing company that focuses on prescription pharmaceuticals, over-the-counter drugs, energy drinks, and nutrition products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's gross profits are derived from the distribution and logistics segments. The company operates in Indonesia but has operations across various ASEAN countries, Nigeria, and South Africa.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Shenzhen Kangtai Biological Products Co Ltd is a human vaccine research and development company. The company is engaged in the research and development, production and sales of recombinant hepatitis B vaccine, b -type influenza Haemophilus conjugate vaccine, measles-rubella combined live attenuated vaccine, cell-free baibai broke b Haemophilus influenzae vaccine and other products.

United Laboratories International Holdings Ltd is mainly engaged in the research and development, production and sales of pharmaceuticals. The company operates in three segments: Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. The majority of the company's sales are generated in China, followed by Europe, India and other countries.

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.

Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.

SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and development of vaccines. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further, it has several other vaccines under development and clinical trials, including a recombinant rotavirus vaccine.

ArsenalBio is a South San Francisco-based, clinical-stage cell therapy company that engineers CAR T-cell therapies using CRISPR-based genome editing and logic-gating technology. Its pipeline targets solid tumors including ovarian, kidney, and prostate cancers, with its lead candidate, AB-2100, in Phase 1/2 trials for clear-cell renal cell carcinoma under a collaboration with Bristol-Myers Squibb. The platform is designed to address T-cell exhaustion, tumor specificity, and genome toxicity, challenges that have limited CAR T therapies in solid tumors.

BioRay Pharmaceuticals is a Shanghai-headquartered biopharma with R&D centers in Taizhou, Hangzhou, San Diego, and over 1,400 employees focused on immunology therapies. It commercializes three products in China for autoimmune diseases including Telitacicept for SLE, with a pipeline of 20 preclinical and 10 clinical assets targeting cancer and inflammation. Founded in 2010, BioRay operates GMP facilities for full-cycle development.

Inari is a West Lafayette-headquartered biotechnology company developing seed traits through multiplex gene editing and predictive design via its SEEDesign platform. The firm targets corn, soybean, and wheat improvements for yield, drought tolerance, and nitrogen use efficiency. Founded in 2016, Inari operates greenhouses and field trial sites across the US Midwest and Brazil. It collaborates with Corteva and Bayer on commercialization pipelines for hybrid varieties suited to diverse climates.